Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vbi Vaccines Inc CS (NQ: VBIV )

0.9161 +0.0543 (+6.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,760,695
Open 0.8855
Bid (Size) 0.9041 (10)
Ask (Size) 0.9125 (8)
Prev. Close 0.8618
Today's Range 0.8401 - 0.9241
52wk Range 0.8280 - 4.310
Shares Outstanding 258,257,494
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
From VBI Vaccines Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 215 companies set new 52-week lows. 
Via Benzinga

Performance

YTD
-62.91%
-62.91%
1 Month
-28.98%
-28.98%
3 Month
-38.93%
-38.93%
6 Month
-67.05%
-67.05%
1 Year
-72.16%
-72.16%

More News

Read More
VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines To Start Clinical Study Of Pan-Coronavirus Vaccine Candidate This Year
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in the B. Riley Securities 2022 Oncology Investor Conference
From VBI Vaccines Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio
From VBI Vaccines Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
Via Talk Markets
VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada
From VBI Vaccines Inc.
Via Business Wire
4 Penny Stocks Insiders Are Buying
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
54 Biggest Movers From Yesterday
Via Benzinga
40 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
Via Benzinga
Exposures Product Safety
61 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.